---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-005574"
form_type: "8-K"
ticker: "OSCR"
cik: "0001568651"
company_name: "Oscar Health, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:56:27.614499+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Oscar Health reaffirms FY2023 guidance and 2024 EBITDA target; no new figures

## Summary
- Reaffirms full year 2023 guidance as provided in Q3 2023 earnings release (Nov 7, 2023).
- Reaffirms target for Total Company Adjusted EBITDA profitability in 2024.
- To provide interim membership update from 2024 open enrollment at JPM conference.
- No specific financial results or new numbers disclosed in this filing.

## SEC filing metadata
- accession: 0001193125-24-005574
- form_type: 8-K
- ticker: OSCR
- cik: 0001568651
- company_name: Oscar Health, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1568651/000119312524005574/0001193125-24-005574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1568651/000119312524005574/d581645d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-005574
- JSON: https://secwatch.observer/filing/0001193125-24-005574.json
- Plain text: https://secwatch.observer/filing/0001193125-24-005574.txt

## Key facts
- Earnings Releases
  Oscar Health, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: The Company will reaffirm the updated full year 2023 guidance that it provided in its financial results press release for the third quarter of 2023 dated November 7, 2023. The Company will also reaffirm its target of Total Company Adjusted EBITDA profitability in 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1568651/000119312524005574/0001193125-24-005574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.